Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

St. Louis, Missouri Clinical Trials

A listing of St. Louis, Missouri clinical trials actively recruiting patient volunteers.

RESULTS

Found (129) clinical trials

M6620 First in Human Study

An Open-Label, First-in-Human Study of the Safety, Tolerability, and Pharmacokinetics (PK) of M6620 in Combination With Cytotoxic Chemotherapy in Participants With Advanced Solid Tumors

Phase

0.0 miles

Learn More »

Pediatric Precision Laboratory Advanced Neuroblastoma Therapy

A prospective open label, multicenter study to evaluate the feasibility and acute toxicity of using molecularly guided therapy in combination with standard therapy followed by maintenance therapy with DFMO in subjects with newly diagnosed high risk neuroblastoma.

Phase

1.42 miles

Learn More »

Trial of Tolcapone With Oxaliplatin for Neuroblastoma

The purpose of this research study is to evaluate an investigational drug (Tolcapone) alone and in combination with oxaliplatin, for relapsed and refractory neuroblastoma. Tolcapone is approved by the U.S. Food and Drug Administration (FDA) for adults, but is an investigational drug in this study because it has not been ...

Phase

1.42 miles

Learn More »

Phase 1 Clinical Trial of Single-Vial ID93 + GLA-SE in Healthy Adults

Subjects will receive a total of two doses administered IM on Days 0 and 56. Subjects will be monitored for approximately 421 days (one year following the last study injection), including safety laboratory analyses done just prior to and 7 days following each study injection. Tears and nasal swabs will ...

Phase

1.42 miles

Learn More »

Safety and Immunogenicity Study of an Influenza Vaccination Strategy Including an H3N2 M2SR Prime Followed by a Seasonal Quadrivalent Inactivated Vaccine Boost in a Pediatric Population 9-17 Years Old

This is a Phase I double-blind, randomized, placebo-controlled study in 50 healthy adolescents and children, 9-17 years of age, inclusive, who are in good health and meet all eligibility criteria. This clinical trial is designed to assess the safety and immunogenicity of a prime-boost regimen of H3N2 M2SR intranasal influenza ...

Phase

1.78 miles

Learn More »

A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors

To assess the safety and tolerability at increasing dose levels of PF-06647020 in patients with advanced solid tumors in order to determine the maximum tolerated dose and select the recommended Phase 2 dose.

Phase

2.9 miles

Learn More »

A Phase 1 Study Evaluating the Safety Tolerability PK and Efficacy of AMG 510 in Subjects With Solid Tumors With a Specific KRAS Mutation.

Evaluate the safety and tolerability of AMG 510 in adult subjects with KRAS p.G12C mutant solid tumors. Estimate the maximum tolerated dose (MTD) and/or a biologically active dose (eg, recommended phase 2 dose [RP2D]) within investigated subject population groups.

Phase

2.9 miles

Learn More »

Characterize the safety, tolerability, ECG effects, pharmacokinetics and immunogenicity of anetumab ravtansine given as single agent and after inhibition of CYP3A4 and P-gp by concomitant administration of itraconazole in subjects with mesothelin-expressing advanced solid cancers

Phase

3.13 miles

Learn More »

A Dose-finding Study of CC-90009 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Myelodysplastic Syndromes

Study CC-90009-AML-001 is an open-label, Phase 1, dose escalation and expansion, first-in-human clinical study of CC-90009 in subjects with relapsed or refractory acute myeloid leukemia (AML) and relapsed or refractory high-risk myelodysplastic syndrome. The dose escalation part (Part A) of the study will evaluate the safety and tolerability of escalating ...

Phase

3.13 miles

Learn More »

A Study of PDR001 in Combination With LCL161 Everolimus or Panobinostat

The purpose of this study is to combine the PDR001 checkpoint inhibitor with several agents with immunomodulatory activity to identify the doses and schedule for combination therapy and to preliminarily assess the safety, tolerability, pharmacological and clinical activity of these combinations.

Phase

3.13 miles

Learn More »